跳至主要内容
临床试验/NCT07270003
NCT07270003招募中不适用

A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis

Xijing Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年10月1日最近更新:
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
60
试验地点
1
主要终点
PPPASI50 response rate (≥50% reduction in PPPASI score)

研究概览

简要总结

What's the problem? Palmoplantar pustulosis (PPP) is a long-term skin condition that mainly affects the palms of hands and soles of feet. It causes red, scaly skin with small, non-infectious blisters (called pustules), and often brings pain, itching, or even joint damage over time. It's more common in women aged 40-58 and makes daily life harder. Right now, treatments for PPP aren't great. Creams (like corticosteroids) make symptoms come back fast. Pills (such as acitretin) work slowly, don't always help, and can have bad side effects. Some strong injectable drugs (biologics) are expensive, need long-term use, and require regular checks for infections-plus they don't work well for many PPP patients.

What's this study trying to do?

This study will test a new pill called ivarmacitinib to see if it works for PPP, and if it's safe. Here's what researchers want to find out:

Does ivarmacitinib reduce PPP symptoms (like blisters and redness)-and how quickly? Does it help with joint problems that sometimes come with PPP? Are there side effects (like infections, headaches, or stomach issues)? And how common or serious are they? Do things like a patient's age, past treatments, or other health issues affect how well ivarmacitinib works? How will the study work? This is a open study (everyone knows they're taking ivarmacitinib) with 60 patients at the First Affiliated Hospital of Air Force Medical University (China).

Who can join? Must be 18 or older, with a confirmed PPP diagnosis. Tried at least one other standard treatment (like pills or creams) that didn't work or caused too many side effects.

Must not have serious health issues like active infections (e.g., tuberculosis, hepatitis), low blood cell counts, or bad liver/kidney problems.

What will patients do? Take one 4mg ivarmacitinib pill every day for 12 weeks. Can't use other drugs or light therapy for PPP during this time (but simple moisturizers or meds for other health issues are okay).

Before the study starts: Doctors will check basic health (age, weight, lifestyle), PPP symptoms, and do blood tests, urine tests, and a chest X-ray.

During the study (Weeks 1, 2, 4, 8, 12): Doctors will check how symptoms are changing, ask if patients have any side effects, and do another round of blood tests at Week 12.

What will researchers look for? Does it work? The main goal is to see how many patients have a 50% or bigger reduction in PPP symptoms by Week 12. They'll also check if symptoms get 75% or 90% better, if joints feel better, and if daily life (like working or sleeping) improves.

Is it safe? Researchers will track all side effects-especially infections, blood clots, stomach aches, or headaches-and how serious they are.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ≥18 years old; clinically/pathologically confirmed PPP; failure/intolerance to ≥1 conventional systemic therapy (12-24 weeks of standard dosing); physician-judged suitability for ivarmacitinib; signed informed consent.

排除标准

  • Lymphocyte count <0.5×10⁹/L, neutrophils <1×10⁹/L, platelets <100×10⁹/L, or hemoglobin <80g/L; serum creatinine >132.6μmol/L, AST/ALT >2×ULN, or total bilirubin >2.0mg/dL; active infections (tuberculosis, hepatitis B/C, systemic candidiasis); other conditions hindering participation or data interpretation.

研究组 & 干预措施

Oral ivarmacitinib 4mg once daily for 12 weeks

Other

干预措施: Ivarmacitinib (Drug)

结局指标

主要结局

PPPASI50 response rate (≥50% reduction in PPPASI score)

时间窗: Week 12

次要结局

未报告次要终点

研究者

发起方
Xijing Hospital
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验